| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 16.09. | Lixte Biotechnology Holdings, Inc.: LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future | 286 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight... ► Artikel lesen | |
| 15.09. | Lixte Biotechnology: Führungswechsel und strategische Neuausrichtung nach Kursrallye | - | Investing.com Deutsch | ||
| 15.09. | BOCA RATON - Lixte Biotechnology refreshes leadership and diversifies assets | 2 | Investing.com | ||
| 15.09. | Lixte Biotechnology Holdings, Inc.: LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy | 394 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NASDAQ:LIXT)... ► Artikel lesen | |
| 11.09. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | LIXTE Biotechnology makes $2.6M initial purchase of digital currency | 1 | Seeking Alpha | ||
| 10.09. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions | 103 | GlobeNewswire (Europe) | BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 05.09. | 24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor | 260 | Newsfile | Denver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, underscores... ► Artikel lesen | |
| 03.09. | Lixte Biotechnology appoints new CFO and board members | 1 | Seeking Alpha | ||
| 25.08. | 24/7 Market News and LIXTE Biotechnology Holdings: 24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets | 6 | GlobeNewswire (USA) | ||
| 19.08. | LIXTE Biotechnology Holdings and 24/7 Market News: 24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the "Too Much of a Good Thing" Strategy for LB-100 | 1 | GlobeNewswire (USA) | ||
| 18.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Provides Corporate Update | 132 | GlobeNewswire (Europe) | -Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory... ► Artikel lesen | |
| 15.08. | LIXTE Biotechnology Holdings and 24/7 Market News: 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025 | 1 | GlobeNewswire (USA) | ||
| 14.08. | LIXTE Biotechnology Holdings and 24/7 Market News: 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025 | 1 | GlobeNewswire (USA) | ||
| 13.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency | 136 | GlobeNewswire (Europe) | PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 07.08. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | LIXTE Biotechnology regains Nasdaq compliance | 2 | Seeking Alpha | ||
| 16.07. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements | 273 | GlobeNewswire (Europe) | PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 11.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,95 | +0,17 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| EVOTEC | 6,972 | +1,54 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,00 | -0,85 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,950 | -3,47 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,370 | -1,33 % | Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results | ||
| MAINZ BIOMED | 1,590 | -1,85 % | Mainz Biomed reports on blood-based screening test for pancreatic cancer | ||
| VIKING THERAPEUTICS | 29,570 | -0,07 % | Viking Therapeutics-Aktie: Die spannendste Adipositas-Wette? | Nach unserem letzten Kauftipp Ende vergangenen Monats hat die Aktie von Viking Therapeutics wieder Fahrt aufgenommen und konnte über 20% zulegen. Vor den kommenden Quartalszahlen kocht die Spannung... ► Artikel lesen | |
| IMMUNITYBIO | 2,115 | -0,24 % | ImmunityBio: Zwischen Hype und Hoffnung | Die Aktie von ImmunityBio hat in den vergangenen eineinhalb Jahren deutlich an Wert verloren, nachdem Finanzierungsbedarf zu einer erheblichen Verwässerung führte. Dennoch rückt das Unternehmen dank... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,500 | 0,00 % | Marinomed Biotech prüft strategische Optionen für Marinosolv-Plattform | Die Marinomed Biotech AG hat bekanntgegeben, eine Prüfung strategischer Optionen für ihre Marinosolv-Plattform einzuleiten. Der Vorstand habe mit Zustimmung des Aufsichtsrats den Start dieses Prozesses... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| CEL-SCI | 7,450 | -7,45 % | CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 | Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive... ► Artikel lesen | |
| ORAGENICS | 1,315 | +1,54 % | ORAGENICS INC - 8-K, Current Report | ||
| FIBROGEN | 8,950 | -5,29 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,012 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
| CAPRICOR | 5,360 | +0,75 % | Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel | SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued... ► Artikel lesen |